---
schema_version: "secwatch.filing_event.v1"
accession: "0001785530-21-000052"
form_type: "8-K"
ticker: "HOWL"
cik: "0001785530"
company_name: "Werewolf Therapeutics, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T10:07:43.349421+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Werewolf Therapeutics Q3 net loss $13.8M; cash $170.4M; Merck collaboration for WTX-124

## Summary
- Net loss of $13.8M versus $6.1M in Q3 2020; R&D expenses $9.8M, G&A $4.0M.
- Cash and equivalents $170.4M, up from $92.6M at year-end 2020; runway through Q2 2023.
- Entered clinical trial collaboration with Merck to evaluate WTX-124 + KEYTRUDA in solid tumors.
- On track to file INDs for WTX-124 and WTX-330 in first half of 2022.
- Appointed Meeta Chatterjee, Ph.D., to board of directors in October 2021.

## SEC filing metadata
- accession: 0001785530-21-000052
- form_type: 8-K
- ticker: HOWL
- cik: 0001785530
- company_name: Werewolf Therapeutics, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1785530/000178553021000052/0001785530-21-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1785530/000178553021000052/howl-20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001785530-21-000052
- JSON: https://secwatch.observer/filing/0001785530-21-000052.json
- Plain text: https://secwatch.observer/filing/0001785530-21-000052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.